Ervin Jeffrey S 4

What Happened

• Jeffrey S. Ervin, Chief Financial Officer of Allarity Therapeutics, Inc. (ALLR), was granted 150,000 restricted stock units (RSUs) on January 28, 2026. The grant is coded as an acquisition/award (Form 4 code A) and shows an acquisition price of $0.00 (standard for RSU awards — no cash exchanged at grant).

Key Details

• Transaction date: January 28, 2026; Filing date: April 30, 2026 (Form 4 accession 0001213900-26-050131).
• Securities granted: 150,000 RSUs; reported acquisition price: $0.00.
• Shares owned after the transaction: Not disclosed in the filing.
• Vesting: Per the filing footnote, the RSUs vest in equal one-third installments on the first, second and third anniversaries of the grant, subject to continued service.
• Timeliness: The Form 4 was filed more than two business days after the transaction date, so the filing appears to be late relative to the usual two-business-day reporting requirement.

Context

• RSU grants are a form of equity compensation, not an immediate purchase or sale. They convert to shares only as they vest; their eventual value depends on Allarity’s future stock price and the recipient’s continued employment. This transaction is routine compensation-related awarding rather than an insider buying (bullish) or selling (liquidity) action.